Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial

Hugo Ford, Janet Dunn, Jonathan Wadsley et al.|The Lancet Oncology|2013

Cited by 604